GPL Femme
GPL® Femme · GPL Femme complex · female geroprotector kit · GPL Femme
GPL Femme is a boxed geroprotector kit: thyroid, vessels, brain, liver, and pineal - Thyreogen, Ventfort, Cerluten, Svetinorm, Endoluten. It is not HRT and not Zhenoluten.
Quick answer
What it is: GPL Femme is a boxed geroprotector kit: thyroid, vessels, brain, liver, and pineal - Thyreogen, Ventfort, Cerluten, Svetinorm, Endoluten.
Class and target: Commercial multi-organ kit · Multi-system (female kit)
Typical research dose: Kit insert (oral capsules)
Open the calculator →What it is & the evidence on The Bioregulator Atlas →
Research summary, not medical advice.
Use-case scores
- Longevity / aging2/10
Compound card
- Class
- Commercial female geroprotector kit (oral; not a single peptide)
- Status
- Not FDA-approved · research use
How it works
GPL Femme is a commercial kit of five organ Cytomaxes (thyroid, vessels, brain, liver, pineal). Zhenoluten (ovary) is not in this kit’s bill of materials.
Source: Cytomed / NPCRIZ commercial kits; class review PMID 11713572
Khavinson map
Adjacent (not padded into the 41)Used in bioregulator stacks
Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.
The Khavinson school
GPL Femme is filed here as commercial multi-organ kit, targeting the multi-system (female kit). Khavinson's St. Petersburg group moved from organ extracts (Cytamins) to capsule complexes (Cytomaxes) to synthetic short peptides (Cytogens); most of the evidence comes from that one group, with little independent Western replication.
Read the full background, the proposed epigenetic mechanism, the literature limits, and how we count the canonical 41 on the Khavinson bioregulators index.
History of this molecule
Same commercial idea as GPL Man: one box instead of five Cytomax bottles. The kit lists thyroid, vessels, brain, liver, pineal. Ovary (Zhenoluten) is not in that bill of materials - if someone is shopping “female reproductive bioregulator,” send them to Zhenoluten, not this kit.
We catalog the kit so the name resolves, then we cross-link the leaves.
Caveats
Not estradiol, not progesterone, not a menopause drug. Thyroid-containing kits are still not levothyroxine.
Full 41-map: Khavinson bioregulators index · Bioregulator stacks
Research Use Cases
- ✓Catalog identity: Low
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Kit insert | Per box | Manufacturer course | Capsules. Not HRT. |
Administration
GPL Femme: Boxed Cytomax kit vs Not a research vial
- The real SKU is capsules in a box.
- Ovary shoppers get sent to Zhenoluten, not this kit.
- Not a sublingual tablet. Nobody manufactures this SKU that way.
- Not in the 41. Not estradiol, not progesterone, not menopause therapy.
- Thyroid-containing kits are still not levothyroxine. Keep prescribed thyroid drugs.
- No kit-level RCT.
- Keeps the kit from inheriting vial math.
- Calculator skip is correct.
- Not an IM extract ampoule.
- Catalogs flatten “female peptide kit” into one syringe. That is a mis-ID.
- Not a sublingual HRT melt.
- Animal-source constraints inherit from every constituent.
Timeline
Who it is for
Catalog identity
LowSearch landing for the boxed female geroprotector.
Safety & Considerations
Not estradiol, not a menopause drug. Thyroid kit ≠ levothyroxine.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Thyroid kit components ≠ levothyroxine.
Verdict
GPL Femme is a kit. Zhenoluten is the ovary Cytomax leaf. This is not HRT.
Interactions & Contraindications
Not estradiol, not a menopause drug. Thyroid kit ≠ levothyroxine.
Frequently Asked Questions
Does GPL Femme include the ovary Cytomax?▼
Is it HRT?▼
Oral capsule or injection?▼
Does this include the ovary Cytomax?▼
References
- Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2001). PMID: 11713572
📚 Related Articles
Prescription options: compare licensed telehealth providers
Some peptide therapies are available only by prescription after a consult with a licensed clinician.
